Package Leaflet: Information for the User
Solifenacin Novalie 10 mg film-coated tablets EFG
Solifenacin, succinate
Read the entire package leaflet carefully before starting to take this medication, as it contains important information for you.
Contents of the Package Leaflet
The active substance in Solifenacin Novalie belongs to the group of anticholinergics. These medications are used to reduce the activity of the overactive bladder. This allows you to have more time before needing to go to the bathroom and increases the amount of urine that your bladder can hold.
Solifenacin Novalie is used to treat the symptoms of overactive bladder syndrome. These symptoms include: having a strong and sudden need to urinate without warning, needing to urinate frequently, or having urine leaks because you cannot get to the bathroom in time.
Do not take Solifenacin Novalie
Before starting treatment with solifenacin, inform your doctor if you have or have had any of the above-mentioned diseases.
Warnings and precautions
Consult your doctor or pharmacist before starting to take this medication.
Children and adolescents
This medication should not be used in children and adolescents under 18 years of age.
Inform your doctor before starting treatment with this medication if any of the above circumstances have ever occurred to you.
Before starting treatment with solifenacin, your doctor will assess if there are other causes for your frequent need to urinate (e.g., heart failure or kidney disease). If you have a urinary tract infection, your doctor will prescribe an antibiotic (treatment against certain bacterial infections).
Using Solifenacin Novalie with other medications
Tell your doctor or pharmacist that you are using, have recently used, or may need to use any other medication. It is especially important to inform your doctor if you are taking:
Using Solifenacin Novalie with food, drinks, and alcohol
This medication can be taken with or without food, as preferred.
Pregnancy, breastfeeding, and fertility
If you are pregnant or breastfeeding, think you may be pregnant, or plan to become pregnant, consult your doctor or pharmacist before using this medication.
Do not use solifenacin if you are pregnant unless it is absolutely necessary.
Do not use solifenacin during breastfeeding, as solifenacin may pass into breast milk.
Driving and using machines
Solifenacin may cause blurred vision and sometimes drowsiness or fatigue. If you experience any of these side effects, do not drive or use machines.
Solifenacin Novalie contains lactose
This medication contains lactose. If your doctor has told you that you have an intolerance to certain sugars, consult with them before taking this medication.
Instructions for correct use
Follow your doctor's instructions for taking this medication exactly. If you are unsure, consult your doctor or pharmacist again.
Swallow the tablet whole with some liquid. It can be taken with or without food, as preferred. Do not crush the tablets.
The recommended dose is 5 mg per day, unless your doctor tells you to take 10 mg per day.
If you take more Solifenacin Novalie than you should
In case of overdose or accidental ingestion, contact your doctor or pharmacist immediately, or call the Toxicology Information Service, phone: 91 562 04 20, indicating the medication and the amount ingested.
Symptoms in case of overdose may include: headache, dry mouth, dizziness, drowsiness, and blurred vision, perception of things that are not there (hallucinations), pronounced excitement, convulsions, difficulty breathing, increased heart rate (tachycardia), urine accumulation in the bladder (urinary retention), and dilation of the pupils (mydriasis).
If you forget to take Solifenacin Novalie
If you forget to take a dose at the usual time, take it as soon as you remember, unless it is time to take the next dose. Never take more than one dose per day. If you are unsure, consult your doctor or pharmacist.
If you stop taking Solifenacin Novalie
If you stop taking solifenacin, your overactive bladder symptoms may return or worsen. Always consult your doctor if you are considering stopping treatment.
If you have any other questions about using this medication, ask your doctor or pharmacist.
Like all medications, this medication can cause side effects, although not everyone will experience them.
If you suffer an allergic reaction or a severe skin reaction (e.g., blistering and peeling of the skin), inform your doctor or nurse immediately.
Angioedema (allergy in the skin that results in inflammation under the skin surface) with respiratory tract obstruction (difficulty breathing) has been reported in some patients treated with solifenacin succinate. If angioedema occurs, treatment with solifenacin succinate should be discontinued immediatelyand appropriate treatment and/or measures should be taken.
Solifenacin may cause the following side effects:
Very common (may affect more than 1 in 10 people)
Common (may affect up to 1 in 10 people)
Uncommon side effects (may affect up to 1 in 100 people)
Rare side effects (may affect up to 1 in 1,000 people)
Very rare side effects (may affect up to 1 in 10,000 people)
Frequency not known (frequency cannot be estimated from available data)
Reporting side effects
If you experience any side effects, consult your doctor or pharmacist, even if they are not listed in this package leaflet. You can also report them directly through the Spanish Medicines and Healthcare Products Agency's website: www.notificaRAM.es.
By reporting side effects, you can help provide more information on the safety of this medication.
Keep this medication out of the sight and reach of children.
This medication does not require special storage conditions.
Do not use Solifenacin Novalie after the expiration date stated on the packaging. The expiration date is the last day of the month indicated.
Medications should not be disposed of via wastewater or household waste. Return the packaging and any unused medication to the pharmacy's SIGRE collection point. If you are unsure, consult your pharmacist on how to dispose of the packaging and any unused medication. This will help protect the environment.
Composition of Solifenacin Novalie
Appearance of the product and package contents
Solifenacin Novalie 10 mg is presented in the form of film-coated tablets, round, pink, and with the inscription "E3" on one side.
Solifenacin Novalie 10 mg film-coated tablets are available in packages of 30 tablets.
Marketing authorization holder
Novalie Pharma, S.L.U.
Calle Jorge Ruiz de Santallana, 51
05005 Avila, Spain
Manufacturer
Neuraxpharm Pharmaceuticals, S.L.
Avda. Barcelona 69
08970 Sant Joan Despí (Barcelona), Spain
This medication is authorized in:
Netherlands Solifenacinesuccinaat Lesvi 10 mg film-coated tablets
Poland Soreca
Spain Solifenacina Novalie 10 mg film-coated tablets
Date of the last revision of this package leaflet: June 2017
Detailed and updated information on this medication is available on the website of the Spanish Agency for Medicines and Healthcare Products (AEMPS), http://www.aemps.gob.es/